<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>983</ReferenceId>
        <DateLastUpdated>2020-10-11-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11164910</PubmedId>
            <Abstract>We analyzed the characteristics of 29 Guillain-Barré syndrome (GBS) patients with IgM anti-GalNAc-GD1a antibodies. Fourteen of them had had an antecedent cytomegalovirus infection (CMV group) and 12 gastrointestinal infection (G-I group). Most of the G-I group patients (nine of 12) were subsequent to Campylobacter jejuni infection. Electrophysiological results in both groups patients predominantly indicated demyelinating neuropathy. The CMV group patients were characterized by slow progression and frequent facial and sensory deficits. IgM antibodies in their sera recognized an epitope shared by GalNAc-GD1a and GM2. The G-I group patients frequently showed motor type of GBS with cranial nerves spared. IgM antibodies specific to GalNAc-GD1a were present in their sera.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>260-7</ArticlePages>
            <ArticleTitle>Guillain-Barré syndrome with IgM antibody to the ganglioside GalNAc-GD1a.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Kaida</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Kusunoki</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Kamakura</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Motoyoshi</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Kanazawa</LastName>
                    <ForeName>I</ForeName>
                </Author>
            </Authors>
            <Affiliations>Third Department of Internal Medicine, National Defense Medical College, Saitama-ken, Japan.</Affiliations>
            <ArticleChemicalList>Antibodies;Gangliosides;Immunoglobulin M;G(M2) Ganglioside;IV(4)-galactosyl-N-acetylganglioside GD1a</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adult; Antibodies(analysis); Campylobacter Infections(complications); Campylobacter jejuni; Cytomegalovirus Infections(complications); Demyelinating Diseases(physiopathology); Electrophysiology; Female; G(M2) Ganglioside(immunology); Gangliosides(immunology); Gastrointestinal Diseases(complications); Guillain-Barre Syndrome(etiology; immunology; physiopathology; therapy); Humans; Immunoglobulin M(analysis); Infections(complications); Male; Middle Aged; Neural Conduction; Prognosis</ArticleMeshHeadingsList>
            <Journal>
                <Volume>113</Volume>
                <Issue>2</Issue>
                <Title>Journal of neuroimmunology</Title>
                <Issn>0165-5728</Issn>
                <MedlineTa>J Neuroimmunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>GalNAc-GD1a</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:59228</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>139966</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 262, Table 2</LocationOfData>
                        <BCellId>1953461</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>GBS patients were tested. This group of patients was previously described in Kaida et al, Brain. 2000 123:116 [PMID:10611126].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <NumberOfSubjectsTested>105</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>16</NumberOfSubjectsResponded>
                            <ResponseFrequency>15.2</ResponseFrequency>
                            <AssayComments>In the GBS patients, high titer of anti-epitope IgG was detected in 16 patients, five of whom were also positive for anti-epitope IgM. Most of these positive patients (87%) had GBS subsequent to gastrointestinal infection symptoms.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:59228</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953462</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>311</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <AssayComments>Cross-reactivity of anti-epitope IgM antibodies to GM2 ganglioside was measured by an ELISA preadsorption test in patients with Gullain-Barré syndrome subsequent to CMV infection.   78% of anti-epitope antibody reactivity was cross-reactive with GM2.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>gangioside GM2</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953460</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>311</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <AssayComments>Cross-reactivity of anti-epitope IgM antibodies to GM2 ganglioside was measured by an ELISA preadsorption test in 12 patients with Gullain-Barré syndrome subsequent to G-I infection. 21% of anti-epitope antibody reactivity was cross-reactive with GM2.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>ganglioside GM2</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 262, Table 1</LocationOfData>
                        <BCellId>1953459</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>GBS patients were tested.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>672</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>29</NumberOfSubjectsResponded>
                            <ResponseFrequency>4.3</ResponseFrequency>
                            <AssayComments>In the 672 GBS patients cohort, 29 are reported to have anti-epitope IgM in the absence of anti-epitope IgG. No data is provided on patients from this cohort with both positive IgM and IgG for this epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:59228</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GM2</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:51013</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>143251</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 1 and 4</LocationOfData>
                        <BCellId>1953464</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>14</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GM2 ganglioside were detected. In a preabsorption experiment, the GM2 ganglioside was able to absorb 78% of the reactivity to GalNAc-GD1a, confirming there is cross-reactivity among the two gangliosides.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953479</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GM2 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953480</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GM2 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 1 and 4</LocationOfData>
                        <BCellId>1953463</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GM2 ganglioside were detected. In a preabsorption experiment, the GM2 ganglioside was able to absorb 21% of the reactivity to GalNAc-GD1a, confirming the cross-reactivity among the two gangliosides is detected but to a small extent in this group.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 264</LocationOfData>
                        <BCellId>1953496</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>GBS patients were tested.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>672</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>0.7</ResponseFrequency>
                            <AssayComments>In the 672 GBS patients cohort, 5 are reported to have anti-epitope IgM without IgM to GalNAc-GD1a or IgG to other gangliosides. No data is reported on how many patients had anti-epitope IgM along with other reactivities.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GM1</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:61048</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>142077</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953482</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GM1 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953483</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GM1 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953465</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GM1 ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953466</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>21.4</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GM1 ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GD1b</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:28175</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>138831</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953485</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GD1b ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953484</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GD1b ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953468</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GD1b ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953467</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GD1b ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GT1b</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:60913</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>144143</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953469</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GT1b ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:60913</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953470</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GT1b ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:60913</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953486</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GT1b ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:60913</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953487</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GT1b ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:60913</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GQ1b</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:27515</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>130673</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953472</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GQ1b ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953471</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GQ1b ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953488</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GQ1b ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953489</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GQ1b ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GD3</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:28424</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>139967</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953474</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GD3 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953473</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GD3 ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953491</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GD3 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953490</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GD3 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GM3</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:15681</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>139968</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953476</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GM3 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:15681</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953475</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GM3 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:15681</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953493</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GM3 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:15681</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953492</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GM3 ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:15681</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GD1a</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:18163</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>139429</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953478</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GD1a ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953477</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgM class antibodies to GD1a ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953494</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients (n=12) with gastrointestinal symptoms and lacking IgM Abs to CMV were tested. Nine of them had proven antecedent C. jejuni infection, either isolated from their stool cultures or serologically proved to have C. jejuni infection. The group of patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to gastrointestinal (mostly C. jejuni) infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GD1a ganglioside were detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953495</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10359</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>GBS patients with IgM Abs to CMV were considered to have antecedent cytomegalovirus infection. In the group of patients tested (n=14), 9 had signs of upper respiratory infection and 1 had fever and headache. The patients tested are those with positive IgM and negative IgG for ganglioside GalNAc-GD1a.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>In patients with Guillian-Barre syndrome subsequent to CMV infection with positive IgM and negative IgG to GalNAc-GD1a, IgG class antibodies to GD1a ganglioside were not detected.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

